• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CryoPort Inc.

    2/14/24 12:22:50 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    SC 13G 1 form_sc13g-cryoport.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

    Cryoport, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    229050307
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [X]  Rule 13d-1(b)

    [_]  Rule 13d-1(c)

    [_]  Rule 13d-1(d)

    __________
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No
    229050307
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Cadian Capital Management, LP
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    3,464,079
     
     
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    7.1% (1)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IA, PN
     

    (1) Based on 48,963,717 shares of Common Stock of Cryoport, Inc. (the “Issuer”) outstanding as of December 1, 2023, as disclosed in the Issuer’s Prospectus filed with the Securities and Exchange Commission (“SEC”) on December 21, 2023.



    CUSIP No
    229050307
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Cadian Capital Management GP, LLC
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    3,464,079
     
     
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    7.1% (1)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    OO, HC
     
     
    (1) Based on 48,963,717 shares of Common Stock of the Issuer outstanding as of December 1, 2023, as disclosed in the Issuer’s Prospectus filed with the SEC on December 21, 2023.




    CUSIP No
    229050307
     
     
     
     
     
    1.
    NAME OF REPORTING PERSONS
     
     
     
     
     
    Eric Bannasch
     
     
     
     
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
     (a)  [_]
     
     
     (b)  [_]
     
     
     
     
    3.
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
     
     
    5.
    SOLE VOTING POWER
     
     
     
     
     
    0
     
     
     
     
    6.
    SHARED VOTING POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    7.
    SOLE DISPOSITIVE POWER
     
     
     
     
     
    0
     
     
     
     
    8.
    SHARED DISPOSITIVE POWER
     
     
     
     
     
    3,464,079
     
     
     
     
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
    3,464,079
     
     
     
     
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
     [_]
     
     
     
     
     
     
     
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
    7.1% (1)
     
     
     
     
    12.
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
    IN, HC
     
     
    (1) Based on 48,963,717 shares of Common Stock of the Issuer outstanding as of December 1, 2023, as disclosed in the Issuer’s Prospectus filed with the SEC on December 21, 2023.



    CUSIP No
    229050307
     
     

    Item 1.
    (a).
    Name of Issuer:
     
     
     
     
    Cryoport, Inc. (the "Issuer")
     

     
    (b).
    Address of Issuer's Principal Executive Offices:
     
     
     
     
    112 Westwood Place, Suite 350
    Brentwood, Tennessee 37027
     

    Item 2.
    (a).
    Name of Person Filing:
     
     
     
     
     
     
     
    Cadian Capital Management, LP
    Cadian Capital Management GP, LLC
    Eric Bannasch
     
    The filing persons named above are collectively referred to herein as the "Reporting Persons."
     

     
    (b).
    Address of Principal Business Office, or if None, Residence:
     
     
     
     
    Cadian Capital Management, LP
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
    Cadian Capital Management GP, LLC
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
    Eric Bannasch
    535 Madison Avenue
    36th Floor
    New York, NY 10022
     
     
     
     
     

     
    (c).
    Citizenship:
     
     
     
     
    Cadian Capital Management, LP – Delaware
    Cadian Capital Management GP, LLC – Delaware
    Eric Bannasch – United States of America
     

     
    (d).
    Title of Class of Securities:
     
     
     
     
     
     
     
    Common Stock, par value $0.001 per share ("Common Stock")
     

     
    (e).
    CUSIP Number:
     
     
     
     
    229050307
     



    Item 3.
     
    If This Statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b), or (c), check whether the person filing is a

     
    (a)
    [_]
    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

     
    (b)
    [_]
    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     
    (c)
    [_]
    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     
    (d)
    [_]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     
    (e)
    [X]
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
     
    (f)
    [_]
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     
    (g)
    [X]
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     
    (h)
    [_]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     
    (i)
    [_]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    [_]
    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     
    (k)
    [_]
    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     
    Item 4.
    Ownership.

     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned:
     
     
     
     
     
    Cadian Capital Management, LP – 3,464,079
    Cadian Capital Management GP, LLC – 3,464,079
    Eric Bannasch – 3,464,079

     
    (b)
    Percent of class:
     
     
     
     
     
    Cadian Capital Management, LP – 7.1%
    Cadian Capital Management GP, LLC – 7.1%
    Eric Bannasch – 7.1%
     
    Such percentages are based on 48,963,717 shares of Common Stock outstanding as of December 1, 2023, as disclosed in the Issuer’s Prospectus filed with the Securities and Exchange Commission on December 21, 2023.



     
    (c)
    Number of shares as to which the person has:

     
     
    Cadian Capital Management, LP

     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    3,464,079
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    3,464,079
    .
     
     
     
     
     

     
     
    Cadian Capital Management GP, LLC

     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    3,464,079
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    3,464,079
    .
     
     
     
     
     

     
     
    Eric Bannasch
     
     
     
     
     
    (i)
    Sole power to vote or to direct the vote
    0
    ,
     
     
     
     
     
     
     
    (ii)
    Shared power to vote or to direct the vote
    3,464,079
    ,
     
     
     
     
     
     
     
    (iii)
    Sole power to dispose or to direct the disposition of
    0
    ,
     
     
     
     
     
     
     
    (iv)
    Shared power to dispose or to direct the disposition of
    3,464,079
    .

    All securities reported in this Schedule 13G are directly held by Cadian Master Fund L.P. (the "Advisory Client"), an advisory client of Cadian Capital Management, LP (the "Adviser"). Pursuant to an Investment Management Agreement between the Advisory Client and the Adviser, the Adviser exercises exclusive voting and investment power over securities directly held by the Advisory Client. Cadian Capital Management GP, LLC is the general partner of the Adviser. Eric Bannasch is the sole managing member of Cadian Capital Management GP, LLC.
     


    Item 5.
    Ownership of Five Percent or Less of a Class.

     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
     
    N/A

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.

     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
     
     
    All securities reported in this Schedule 13G are directly held by the Advisory Client.
     
     

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
     
    The disclosure regarding the relationships among the Reporting Persons in Item 4 is incorporated by reference herein.
     
     

    Item 8.
    Identification and Classification of Members of the Group.
     
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
     
     
    N/A
     
     

    Item 9.
    Notice of Dissolution of Group.

     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
     
    N/A

     
    Item 10.
     
    Certification.

     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     



    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     

     
    February 14, 2024
     
    (Date)

     
     
     
    Cadian Capital Management, LP
     
     
    By: Cadian Capital Management GP, LLC, its General Partner
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
    Cadian Capital Management GP, LLC 
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
     
    /s/  Eric Bannasch
     
    Eric Bannasch






    EXHIBIT INDEX

    99.1
    Joint Filing Agreement, dated as of February 14, 2024, by and among the Reporting Persons
     
     

     

     




    Exhibit 99.1
     
    AGREEMENT
     
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Schedule 13G (including additional amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Cryoport, Inc.  This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.
     
     Dated:  February 14, 2024

     
     
     
    Cadian Capital Management, LP
     
     
    By: Cadian Capital Management GP, LLC, its General Partner
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
    Cadian Capital Management GP, LLC 
     
     
    By:  /s/ Eric Bannasch
     
    Eric Bannasch
     
    Managing Member
     
     
     
    /s/  Eric Bannasch
     
    Eric Bannasch

    Get the next $CYRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    5/3/2024$22.00 → $19.00Buy → Neutral
    B. Riley Securities
    4/4/2024$17.00 → $21.00Buy
    Jefferies
    3/13/2024$19.00 → $18.00Buy
    Needham
    More analyst ratings

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

      DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the

      3/31/25 9:06:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hariri Robert J sold $76,250 worth of shares (12,500 units at $6.10), decreasing direct ownership by 61% to 8,061 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      5/30/25 7:00:17 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Sawicki Mark W sold $9,364 worth of shares (1,349 units at $6.94), decreasing direct ownership by 2% to 84,087 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      3/26/25 7:01:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Stefanovich Robert sold $7,428 worth of shares (1,070 units at $6.94), decreasing direct ownership by 0.56% to 190,349 units (SEC Form 4)

      4 - Cryoport, Inc. (0001124524) (Issuer)

      3/26/25 7:00:42 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CryoPort Inc.

      SC 13G - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 4:02:52 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/14/24 1:34:13 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

      SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

      11/13/24 7:16:51 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

      Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

      1/14/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport Announces Appointment of Linda Baddour to its Board of Directors

      NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

      3/3/21 4:08:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Appoints Martin Schmieg to Board of Directors

      BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

      12/1/20 6:30:00 AM ET
      $BCTX
      $CLBS
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Managed Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cryoport upgraded by UBS with a new price target

      UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00

      3/24/25 8:25:01 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Cryoport with a new price target

      Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:39 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Cryoport with a new price target

      Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00

      12/19/24 7:35:29 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    Financials

    Live finance-specific insights

    See more
    • Cryoport Reports First Quarter 2025 Financial Results

      Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025.  Jerrell Shelton, C

      5/7/25 4:05:00 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025

      NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,

      4/24/25 8:30:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

      DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the

      3/31/25 9:06:00 AM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYRX
    SEC Filings

    See more
    • SEC Form SD filed by CryoPort Inc.

      SD - Cryoport, Inc. (0001124524) (Filer)

      5/30/25 4:31:07 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

      SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

      5/15/25 7:41:28 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

      SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

      5/15/25 12:34:32 PM ET
      $CYRX
      Biotechnology: Pharmaceutical Preparations
      Health Care